Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 10:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Age - Related Macular Degeneration (AMD) Clear all
Completed No phase listed Observational

Vision Outcomes Using Quantitative Optical Coherence Tomography Evaluation in Age Related Macular Degeneration

NCT02422160
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
No interventions are planned
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 16, 2022 · Synced Jul 24, 2026, 10:02 AM EDT
Active, not recruiting Phase 4 Interventional

A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

NCT06795048
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration (nAMD)
Interventions
Faricimab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
11
States / cities
Santa Ana, California • Orlando, Florida • Winter Haven, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Jul 24, 2026, 10:02 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Pilot Study of the Evaluation of Subconjunctival Sirolimus in the Treatment of Bilateral GA Associated With AMD

NCT00766649
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Sirolimus
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
55 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Jul 24, 2026, 10:02 AM EDT
Recruiting Phase 1 Interventional

Evaluating the Safety and Tolerability of Orally Administered DF-003 in ROSAH Syndrome Patients

NCT06395285
View directory record Official record
Conditions
ROSAH
Interventions
DF-003
Drug
Lead sponsor
Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm)
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Bethesda, Maryland • Durham, North Carolina • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jul 24, 2026, 10:02 AM EDT
Completed Phase 3 Interventional Results available

A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD)

NCT03150589
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
SB11 (Proposed ranibizumab biosimilar), Lucentis (ranibizumab)
Drug
Lead sponsor
Samsung Bioepis Co., Ltd.
Industry
Eligibility
50 Years and older
Enrollment
705 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
19
States / cities
Poway, California • Colorado Springs, Colorado • Fort Myers, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated May 20, 2021 · Synced Jul 24, 2026, 10:02 AM EDT
Completed Phase 2 Interventional Results available

Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration

NCT02358889
View directory record Official record
Conditions
Choroidal Neovascularization, Age-related Macular Degeneration
Interventions
hI-con1, ranibizumab, Sham injection
Biological · Other
Lead sponsor
Iconic Therapeutics, Inc.
Industry
Eligibility
50 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
48
States / cities
Phoenix, Arizona • Arcadia, California • Beverly Hills, California + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Jul 24, 2026, 10:02 AM EDT
Completed No phase listed Observational

Evaluation and Treatment of Patients With Retinal Disease

NCT00005784
View directory record Official record
Conditions
Retinal Disease
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
10 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 24, 2026, 10:02 AM EDT
Completed Phase 2 Interventional Results available

LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Wet Age-Related Macular Degeneration

NCT02355028
View directory record Official record
Conditions
Exudative Age-Related Macular Degeneration
Interventions
LHA510 ophthalmic suspension, LHA510 vehicle, Ranibizumab ophthalmic solution
Drug
Lead sponsor
Alcon, a Novartis Company
Industry
Eligibility
50 Years to 90 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2018 · Synced Jul 24, 2026, 10:02 AM EDT
Terminated Phase 3 Interventional Results available

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion

NCT03802630
View directory record Official record
Conditions
Branch Retinal Vein Occlusion
Interventions
Brolucizumab 6 mg, Aflibercept 2 mg, Sham injection
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
26
States / cities
Phoenix, Arizona • Mountain View, California • Santa Barbara, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2023 · Synced Jul 24, 2026, 10:02 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD)

NCT00775411
View directory record Official record
Conditions
Choroidal Neovascularization, Age-Related Maculopathy
Interventions
dexamethasone, ranibizumab
Drug · Biological
Lead sponsor
Allergan
Industry
Eligibility
50 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2012 · Synced Jul 24, 2026, 10:02 AM EDT
Completed Not applicable Interventional

Macular Degeneration and Aging Study

NCT02224963
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
Preventive Problem-Solving Training, Life and Health Review
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
60 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Jul 24, 2026, 10:02 AM EDT
Completed No phase listed Observational

Age-Related Macular Degeneration (AMD) - Beta Study Telemedicine Assessment

NCT01083147
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
FORESEE HOME
Device
Lead sponsor
Notal Vision Ltd.
Industry
Eligibility
50 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Toms River, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 22, 2010 · Synced Jul 24, 2026, 10:02 AM EDT
Suspended Phase 1 Interventional

Weekly Vaccination With Copaxone as a Potential Therapy for Dry Age-related Macular Degeneration

NCT00541333
View directory record Official record
Conditions
Dry Age Related Macular Degeneration
Interventions
Copaxone Injection
Drug
Lead sponsor
The New York Eye & Ear Infirmary
Other
Eligibility
50 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 2, 2013 · Synced Jul 24, 2026, 10:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

QA102 Phase 1 Study in Healthy Young and Older Adult Subjects

NCT04894071
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
QA102, Placebo
Drug
Lead sponsor
Smilebiotek Zhuhai Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 13, 2022 · Synced Jul 24, 2026, 10:02 AM EDT
Completed Phase 3 Interventional Results available

A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR)

NCT00891735
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
Ranibizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years and older
Enrollment
1,097 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
99
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 91 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Jul 24, 2026, 10:02 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Use of Self-management Group to Improve Quality of Life in Patients With Low Vision

NCT03046485
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
Self management program 'Living with Vision Loss'
Behavioral
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
55 Years to 95 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Jul 24, 2026, 10:02 AM EDT
Completed Phase 2 Interventional

Celecoxib to Treat Macular Degeneration in Patients Receiving Photodynamic Therapy

NCT00043680
View directory record Official record
Conditions
Macular Degeneration
Interventions
Celecoxib
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 24, 2026, 10:02 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Tracking Optical Coherence Tomography

NCT00343603
View directory record Official record
Conditions
Macular Degeneration, Glaucoma, Diabetic Retinopathy, Choroidal Disease
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2011
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 24, 2016 · Synced Jul 24, 2026, 10:02 AM EDT
Recruiting Not applicable Interventional

Stem Cell Ophthalmology Treatment Study II

NCT03011541
View directory record Official record
Conditions
Retinal Disease, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease, Optic Neuropathy, Nonarteritic Ischemic Optic Neuropathy, Optic Atrophy, Optic Nerve Disease, Glaucoma, Leber Hereditary Optic Neuropathy, Blindness, Vision Loss Night, Vision Loss Partial, Vision, Low, Retinopathy, Maculopathy, Macular Degeneration, Retina Atrophy
Interventions
Arm 1
Procedure
Lead sponsor
MD Stem Cells
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
2
States / cities
Westport, Connecticut • Coral Springs, Florida
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Jul 24, 2026, 10:02 AM EDT
Terminated No phase listed Observational

Novel Quantification Methods for Fluorescence to Detect Progression in Stargardt Disease

NCT01676766
View directory record Official record
Conditions
Stargardt Disease
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
5 Years to 18 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Jul 24, 2026, 10:02 AM EDT
Recruiting Phase 2 Interventional

A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema

NCT06962839
View directory record Official record
Conditions
Macular Edema
Interventions
BI 1815368, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
23
States / cities
Arcadia, California • Huntington Beach, California • Modesto, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 24, 2026, 10:02 AM EDT
Completed Not applicable Interventional Results available

Triamcinolone vs. Laser for Diabetic Macular Edema

NCT00229931
View directory record Official record
Conditions
DIABETIC MACULAR EDEMA
Interventions
Triamcinolone acetonide, laser
Drug · Procedure
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced Jul 24, 2026, 10:02 AM EDT
Completed Phase 3 Interventional Results available

Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab

NCT01748292
View directory record Official record
Conditions
Macular Degeneration
Interventions
0.5 mg ranibizumab
Drug
Lead sponsor
Charles C Wykoff, PhD, MD
Other
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
4
States / cities
West Columbia, South Carolina • Houston, Texas • Katy, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2019 · Synced Jul 24, 2026, 10:02 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Genetic Factors in Age-Related Macular Degeneration

NCT00058695
View directory record Official record
Conditions
Macular Degeneration
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
50 Years and older
Enrollment
477 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Jul 24, 2026, 10:02 AM EDT